EMA seeks executive director

Andreas Pott will be acting executive director until position is filled

The European Medicines Agency (EMA) is seeking a new executive director. Its current head, Thomas Lönngren, is leaving the post on 31 December, following the end of his second five-year mandate.

While EMA searches for a permanent replacement, its current head of administration, Andreas Pott, will serve as acting executive director.

University of Hamburg graduate, Pott has been the agency’s administration chief since 2000, having previously worked for the European Parliament and the EU’s translation service.

Swede Lönngren is a former deputy director-general of the Swedish Medical Products Agency (MPA).

You may also like

Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Subscribe now